- Home
- DAVA vs ACRS Comparison
DAVA vs ACRS Comparison
Compare DAVA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | ACRS |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.7M | 314.2M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DAVA | ACRS |
|---|---|---|
| Price | $5.09 | $3.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $16.33 | $9.75 |
| AVG Volume (30 Days) | 473.4K | ★ 3.1M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.26 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,015,391,026.00 | $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $5.03 | $1.05 |
| 52 Week High | $34.94 | $4.89 |
Technical Indicators
Market Signals| Indicator | DAVA | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 25.89 | 50.17 |
| Support Level | $5.03 | $3.38 |
| Resistance Level | $6.53 | $3.80 |
| Average True Range (ATR) | 0.30 | 0.48 |
| MACD | -0.17 | -0.05 |
| Stochastic Oscillator | 5.46 | 34.21 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.